Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1561 participants.

Also called NCT03399370

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,561 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03399370
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03399370. Randomized; double masking; primary purpose treatment. Start 2017-12-21 (actual); primary completion 2019-09-10 (actual). Results posted on 2020-10-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
Acronym
ORION-10
Condition
ASCVD
Condition
Elevated Cholesterol
Intervention (Drug)
Inclisiran Sodium
Intervention (Drug)
Placebo
Lead sponsor
The Medicines Company (class: industry)

Record details

Record id
cardio:ct-nct03399370
Content hash
dda531ef0cfeb49e21593385903c79de439a70780a4a827e0df3c215e28634e4